Sub-Visible Particles: Impact On Therapeutic Proteins
News Jun 07, 2013
SP Scientific has announced a new LyoLearn webinar, due to run on 27th June 2013, entitled 'Sub-visible Particles: Impacts on Aggregation Pathways, Adverse Immunogenicity and Regulatory Expectations for Therapeutic Proteins'.
During the session, Dr. John Carpenter Professor of Pharmaceutical Sciences and Co-Director of the Center for Pharmaceutical Biotechnology, University of Colorado (USA), discusses key areas and presents the latest results from his research.
In addition, he will highlight the particle counting instruments that have been vital to the progress made to date.
Over the past several years there has been greatly increasing attention on sub-visible particles in therapeutic protein products.
Initially, much of the discussion and debate in the field has centred on the utility and need for quantifying particles smaller than 10 micron.
As appropriate instruments and quantitative methods have been developed, valuable progress has occurred in a wide range of drug development areas and more clearly defining critical quality attributes and regulatory expectations related to sub-visible particles.
SP Scientific's program of free educational webinars delivered by industry experts are devoted to lyophilization, freeze-drying and related topics.
LyoLearn webinars follow a 45-minute format for the presentations with a Q&A session immediately afterwards.
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE